ASCO 2023 | Validating efficacy signal in neoadjuvant regimens for GBM: a call for larger randomized trials

Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA, shares the next steps of a Phase II trial (NCT04225039) of retifanlimab and INCAGN01876, a PD-1 inhibitor and GITR agonist respectively with fractionated stereotactic radiotherapy (FSRT) in patients with recurrent glioblastoma (rGBM) The trial observed an improvement in overall-survival (OS) and progression-free survival (PFS) in patients who received FSRT in the non-surgical arm. Dr Bagley highlights the need for a larger randomized trial to validate the efficacy signal observed. The plan is to conduct a randomized Phase II study in patients requiring surgical resection of their GBM. The study will compare different neoadjuvant regimens, including PD-1 inhibition with CRT, PD-1 inhibition alone, and FSR alone, aiming to determine whether the combination approach genuinely improves outcomes for these patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.